Supergen Will Pursue Orathecin As Combo Therapy Following NDA Withdrawal

Withdrawal of NDA for second-line treatment of pancreatic cancer is “most prudent course of action,” firm says following talks last week with FDA. Supergen is moving ahead with a combination trial with gemcitabine.